EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Preoperative Platelet-to-Lymphocyte Ratio as a Predictor of Recurrence and Recurrence-Free Survival in Non-Muscle-Invasive Bladder Cancer Across Different Intravesical Therapies

Muhammet İhsan Öztürk iD, Musa Ekici, Cemil Aydın, Mustafa Serdar Çağlayan, Mücahit Doğan, Mehmet Murat Baykam

Journal of Clinical Medicine · 03.07.2026 · 15 (13) · 5199

DOI: 10.3390/jcm15135199 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 03.07.2026. Verfasst von Muhammet İhsan Öztürk und 5 weiteren Autor:innen. Beteiligte Einrichtung: Alaca State Hospital, Çorum 19600, Turkey. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Non-muscle invasive bladder cancer (NMIBC) is characterized by high recurrence rates despite appropriate treatment and surveillance. Identifying inexpensive and readily available biomarkers capable of improving risk stratification remains an important clinical challenge. The platelet-to-lymphocyte ratio (PLR), a marker of systemic inflammation, has emerged as a potential prognostic indicator in several malignancies. This study aimed to evaluate the association between preoperative PLR, tumor recurrence, and recurrence-free survival (RFS) in NMIBC patients treated with intravesical Bacillus Calmette–Guérin (BCG) or thermochemotherapy.

Methods

This retrospective study included 153 patients diagnosed with NMIBC between January 2020 and January 2024. All patients underwent transurethral resection of bladder tumor (TURBT) followed by intravesical BCG (n = 123) or thermochemotherapy (n = 30). Preoperative PLR was calculated from complete blood counts obtained before surgery. Receiver operating characteristic (ROC) analysis was used to determine the optimal PLR cut-off value. Recurrence-free survival was evaluated using Kaplan–Meier survival analysis and Cox proportional hazards regression models.

Results

During a mean follow-up period of approximately 19 months, recurrence was observed in 35.8% of patients treated with BCG and 30% of those treated with thermochemotherapy. ROC analysis demonstrated good discriminatory ability for recurrence prediction (AUC = 0.831, 95% CI: 0.761–0.901, p < 0.001) and identified an optimal PLR threshold of 120. Patients with elevated PLR values demonstrated higher recurrence rates and shorter recurrence-free survival. Kaplan–Meier analysis revealed a clear separation of survival curves according to PLR status. In multivariable Cox regression analysis, PLR > 120 remained independently associated with recurrence-free survival in the BCG group (HR = 2.703, 95% CI: 1.118–6.534, p = 0.027), whereas only a borderline association was observed in the thermochemotherapy group (HR = 23.265, 95% CI: 0.952–568.336, p = 0.054).

Conclusions

Elevated preoperative PLR was associated with recurrence and recurrence-free survival in patients with NMIBC. The prognostic value of PLR appeared to be more pronounced in patients receiving intravesical BCG therapy. Given its low cost, accessibility, and ease of calculation, PLR may serve as a useful adjunctive biomarker for clinical risk stratification when used alongside established clinicopathological prognostic factors. Further prospective multicenter studies are required to validate these findings.

Schlagwörter

Stichwörter der Autor:innen

Bacillus Calmette–Guérininflammation markersintravesical therapynon-muscle invasive bladder cancerplatelet-to-lymphocyte ratiorecurrencerecurrence-free survivalthermochemotherapyuro-oncology

Autor:innen und Institutionen

  • Alaca State Hospital, Çorum 19600, Turkey.
  • Department of Urology, Faculty of Medicine, Hitit University, Çorum 19040, Turkey.
  • Mengücek Gazi Training and Research Hospital, Erzincan 24100, Turkey.

ORCID-Profile: Muhammet İhsan Öztürk

Zitieren

APA

Öztürk, M. İ., Ekici, M., Aydın, C., Çağlayan, M. S., Doğan, M., & Baykam, M. M. (2026). Preoperative Platelet-to-Lymphocyte Ratio as a Predictor of Recurrence and Recurrence-Free Survival in Non-Muscle-Invasive Bladder Cancer Across Different Intravesical Therapies. Journal of Clinical Medicine, 15(13), 5199. https://doi.org/10.3390/jcm15135199

Vancouver

Öztürk Mİ, Ekici M, Aydın C, Çağlayan MS, Doğan M, Baykam MM. Preoperative Platelet-to-Lymphocyte Ratio as a Predictor of Recurrence and Recurrence-Free Survival in Non-Muscle-Invasive Bladder Cancer Across Different Intravesical Therapies. Journal of Clinical Medicine. 2026;15(13):5199. doi:10.3390/jcm15135199

BibTeX
@article{ztrk2026,
  author = {Öztürk, Muhammet İhsan and Ekici, Musa and Aydın, Cemil and Çağlayan, Mustafa Serdar and Doğan, Mücahit and Baykam, Mehmet Murat},
  title = {Preoperative Platelet-to-Lymphocyte Ratio as a Predictor of Recurrence and Recurrence-Free Survival in Non-Muscle-Invasive Bladder Cancer Across Different Intravesical Therapies},
  journal = {Journal of Clinical Medicine},
  year = {2026},
  volume = {15},
  number = {13},
  pages = {5199},
  doi = {10.3390/jcm15135199}
}
Kostenlos starten →